A drug for treating prostate cancer has been linked with increased risk of dementia, study finds
Getty Images/Andrew Burton
- Prostate cancer patients who take a hormone-suppressing drug may be at an increased risk for dementia and Alzheimer's, a study has found.
- The study of more than 150,000 men found a link between the degenerative diseases and a treatment drug called androgen deprivation therapy.
- Researchers cautioned doctors to further consider the risks of ADT before giving it to their patients to treat prostate cancer.
- Visit Business Insider's homepage for more stories.
A study of more than 150,000 men with prostate cancer found that a certain hormone treatment is linked with increased risks of dementia and Alzheimer's.There's a 20-percent higher chance of having dementia for older men who have taken the prostate cancer treatment, according to the research study from JAMA Network. That drug treatment, called androgen deprivation therapy (ADT), is used to suppress male hormones (like testosterone) that can help to spread prostate cancer in the body.Advertisement
The research study looked at over 150,000 men, age 66 or older, that had been diagnosed with prostate cancer. Researchers monitored participants over a period of at least 10 years after diagnoses.
Among those that were given ADT to treat their prostate cancer, there was a 20-percent increase in risk of dementia and a 14-percent higher risk of Alzheimer's disease.Read more: Nursing homes are giving Alzheimer's patients baby dolls as a form of therapy
"Our results suggest that clinicians need to carefully weigh the long-term risks and benefits of exposure to ADT in patients with a prolonged life expectancy and stratify patients based on dementia risk prior to ADT initiation," the researchers wrote in their study.The study also found that the risk of dementia and Alzheimer's increased with the number of doses of ADT patients were given.Advertisement
- Best yoga mats
- IndiGo to raise ₹4,000 crore through stake sale
- Supreme Court adjourns AGR case hearing to August 14
- ICICI Bank sets floor price for QIP at ₹351.36 per share — to decide on allotment on August 14
- McKinsey, Facebook, Amazon, Nokia — and some other companies looking for a product manager right now